Of note, anti-IL-4 mAb also reduced the activity of anti-PD-1 on tumor growth as observed with FTY720 or FX-1 treatment, a finding compatible with a partial role of peripheral T cells during anti-PD-1 therapy (Fig. S5 J). Here, RPL17 is linked to neoplasm.